EA031766B1 - Ингибиторы альдостеронсинтазы - Google Patents

Info

Publication number

EA031766B1

EA031766B1 EA201790830A EA201790830A EA031766B1 EA 031766 B1 EA031766 B1 EA 031766B1 EA 201790830 A EA201790830 A EA 201790830A EA 201790830 A EA201790830 A EA 201790830A EA 031766 B1 EA031766 B1 EA 031766B1

Authority

EA

Eurasian Patent Office

Prior art keywords

mmol

alkyl

dioxin

compound

heterocyclyl

Prior art date

2014-10-15

Links

• Espacenet
• Global Dossier
• Discuss

• 229940123338 Aldosterone synthase inhibitor Drugs 0.000 title description 3
• 150000001875 compounds Chemical class 0.000 claims abstract description 172
• 150000003839 salts Chemical class 0.000 claims abstract description 43
• 238000011282 treatment Methods 0.000 claims abstract description 12
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
• 125000000217 alkyl group Chemical group 0.000 claims description 59
• 125000000623 heterocyclic group Chemical group 0.000 claims description 40
• 108010009911 Cytochrome P-450 CYP11B2 Proteins 0.000 claims description 23
• 102100024329 Cytochrome P450 11B2, mitochondrial Human genes 0.000 claims description 22
• 230000000694 effects Effects 0.000 claims description 20
• 229910052739 hydrogen Inorganic materials 0.000 claims description 16
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
• 230000005764 inhibitory process Effects 0.000 claims description 14
• 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 14
• 229910052799 carbon Inorganic materials 0.000 claims description 12
• 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 10
• 201000010099 disease Diseases 0.000 claims description 8
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
• 125000003386 piperidinyl group Chemical group 0.000 claims description 8
• 239000003814 drug Substances 0.000 claims description 7
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 6
• 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 6
• 125000002393 azetidinyl group Chemical group 0.000 claims description 6
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
• 208000035475 disorder Diseases 0.000 claims description 6
• 125000002757 morpholinyl group Chemical group 0.000 claims description 6
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 6
• MESFXNGUDNODTJ-UHFFFAOYSA-N 2h-thiazine 1,1-dioxide Chemical compound O=S1(=O)NC=CC=C1 MESFXNGUDNODTJ-UHFFFAOYSA-N 0.000 claims description 5
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 5
• 125000000160 oxazolidinyl group Chemical group 0.000 claims description 5
• 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 5
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
• 239000003937 drug carrier Substances 0.000 claims description 3
• 230000002401 inhibitory effect Effects 0.000 claims description 2
• 238000004519 manufacturing process Methods 0.000 claims 1
• 239000000546 pharmaceutical excipient Substances 0.000 claims 1
• 238000000034 method Methods 0.000 abstract description 54
• 239000000543 intermediate Substances 0.000 abstract description 52
• 208000037765 diseases and disorders Diseases 0.000 abstract description 5
• 230000008569 process Effects 0.000 abstract description 5
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 264
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 135
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 108
• 239000000203 mixture Substances 0.000 description 98
• -1 —OH Chemical group 0.000 description 80
• 235000019439 ethyl acetate Nutrition 0.000 description 67
• 239000000243 solution Substances 0.000 description 64
• 239000011541 reaction mixture Substances 0.000 description 62
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 54
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 52
• 238000003818 flash chromatography Methods 0.000 description 47
• 239000000741 silica gel Substances 0.000 description 44
• 229910002027 silica gel Inorganic materials 0.000 description 44
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 38
• 239000012044 organic layer Substances 0.000 description 34
• 238000006243 chemical reaction Methods 0.000 description 33
• 239000010410 layer Substances 0.000 description 31
• 150000001408 amides Chemical class 0.000 description 28
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 25
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 22
• PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 22
• PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 22
• 229960002478 aldosterone Drugs 0.000 description 22
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 22
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 18
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 18
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
• 239000012267 brine Substances 0.000 description 18
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 18
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 16
• 239000012043 crude product Substances 0.000 description 16
• 239000007787 solid Substances 0.000 description 16
• LXOHISCRPIDIIG-UHFFFAOYSA-N 1,4-dioxine-2-carboxylic acid Chemical compound OC(=O)C1=COC=CO1 LXOHISCRPIDIIG-UHFFFAOYSA-N 0.000 description 15
• 239000000047 product Substances 0.000 description 15
• 229920006395 saturated elastomer Polymers 0.000 description 14
• 239000011734 sodium Substances 0.000 description 14
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 13
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 13
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 13
• 102000003979 Mineralocorticoid Receptors Human genes 0.000 description 13
• 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 13
• 125000003118 aryl group Chemical group 0.000 description 13
• 208000033679 diabetic kidney disease Diseases 0.000 description 13
• 239000000706 filtrate Substances 0.000 description 13
• 150000004702 methyl esters Chemical class 0.000 description 13
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
• 239000003153 chemical reaction reagent Substances 0.000 description 12
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
• 230000015572 biosynthetic process Effects 0.000 description 11
• 239000000460 chlorine Substances 0.000 description 11
• IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 10
• 239000005909 Kieselgur Substances 0.000 description 10
• 125000004093 cyano group Chemical group *C#N 0.000 description 10
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 10
• PSJHLNFXHMZSSM-UHFFFAOYSA-N methyl 2-bromo-1,4-benzodioxine-5-carboxylate Chemical compound COC(=O)C1=CC=CC=2OC(=COC=21)Br PSJHLNFXHMZSSM-UHFFFAOYSA-N 0.000 description 10
• 238000004808 supercritical fluid chromatography Methods 0.000 description 10
• QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 10
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
• 206010020571 Hyperaldosteronism Diseases 0.000 description 9
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
• 125000004429 atom Chemical group 0.000 description 9
• 239000002552 dosage form Substances 0.000 description 9
• 201000009395 primary hyperaldosteronism Diseases 0.000 description 9
• 238000000746 purification Methods 0.000 description 9
• 229910052717 sulfur Inorganic materials 0.000 description 9
• 238000003786 synthesis reaction Methods 0.000 description 9
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
• 238000007792 addition Methods 0.000 description 8
• 229910021529 ammonia Inorganic materials 0.000 description 8
• 125000004432 carbon atom Chemical group C* 0.000 description 8
• 125000001841 imino group Chemical group [H]N=* 0.000 description 8
• 229910052757 nitrogen Inorganic materials 0.000 description 8
• 229910052760 oxygen Inorganic materials 0.000 description 8
• SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 8
• 239000002904 solvent Substances 0.000 description 8
• 238000003756 stirring Methods 0.000 description 8
• DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
• MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 7
• 229960000583 acetic acid Drugs 0.000 description 7
• 210000004100 adrenal gland Anatomy 0.000 description 7
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 7
• 239000001257 hydrogen Substances 0.000 description 7
• 229910052763 palladium Inorganic materials 0.000 description 7
• 150000003254 radicals Chemical class 0.000 description 7
• 239000000725 suspension Substances 0.000 description 7
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 6
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
• 206010020772 Hypertension Diseases 0.000 description 6
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
• PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
• 239000007864 aqueous solution Substances 0.000 description 6
• 229910052786 argon Inorganic materials 0.000 description 6
• 238000003556 assay Methods 0.000 description 6
• NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 6
• UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
• 235000019253 formic acid Nutrition 0.000 description 6
• 125000001072 heteroaryl group Chemical group 0.000 description 6
• 210000003734 kidney Anatomy 0.000 description 6
• 230000001404 mediated effect Effects 0.000 description 6
• 229910052698 phosphorus Inorganic materials 0.000 description 6
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
• HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 6
• 206010016654 Fibrosis Diseases 0.000 description 5
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
• 239000002253 acid Substances 0.000 description 5
• 239000013543 active substance Substances 0.000 description 5
• 239000002671 adjuvant Substances 0.000 description 5
• 230000008901 benefit Effects 0.000 description 5
• ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 5
• 229940113088 dimethylacetamide Drugs 0.000 description 5
• 206010061989 glomerulosclerosis Diseases 0.000 description 5
• 229910052736 halogen Inorganic materials 0.000 description 5
• 150000002367 halogens Chemical class 0.000 description 5
• 210000002216 heart Anatomy 0.000 description 5
• 125000005842 heteroatom Chemical group 0.000 description 5
• 229960000890 hydrocortisone Drugs 0.000 description 5
• 238000005984 hydrogenation reaction Methods 0.000 description 5
• 239000002245 particle Substances 0.000 description 5
• 239000000651 prodrug Substances 0.000 description 5
• 229940002612 prodrug Drugs 0.000 description 5
• 239000000126 substance Substances 0.000 description 5
• 230000002861 ventricular Effects 0.000 description 5
• WDVDHJLKXYCOFS-UHFFFAOYSA-N (5-bromopyridin-3-yl)methanol Chemical compound OCC1=CN=CC(Br)=C1 WDVDHJLKXYCOFS-UHFFFAOYSA-N 0.000 description 4
• AJOKNAMWNODTDW-UHFFFAOYSA-N 2-[5-[1-(2-methylpropanoyl)piperidin-4-yl]oxypyridin-3-yl]-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid Chemical compound C(C(C)C)(=O)N1CCC(CC1)OC=1C=C(C=NC=1)C1COC2=C(O1)C=CC=C2C(=O)O AJOKNAMWNODTDW-UHFFFAOYSA-N 0.000 description 4
• KYXYKZXZSLFBQG-UHFFFAOYSA-N 2-bromo-1,4-benzodioxine-5-carboxamide Chemical compound BrC1=COC2=C(O1)C=CC=C2C(=O)N KYXYKZXZSLFBQG-UHFFFAOYSA-N 0.000 description 4
• AJQDEUJYFUHVHS-UHFFFAOYSA-N 3-bromo-5-(bromomethyl)pyridine Chemical compound BrCC1=CN=CC(Br)=C1 AJQDEUJYFUHVHS-UHFFFAOYSA-N 0.000 description 4
• VNYBIBSZZDAEOK-UHFFFAOYSA-N 5-bromopyridin-3-ol Chemical compound OC1=CN=CC(Br)=C1 VNYBIBSZZDAEOK-UHFFFAOYSA-N 0.000 description 4
• 206010007559 Cardiac failure congestive Diseases 0.000 description 4
• 208000024172 Cardiovascular disease Diseases 0.000 description 4
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
• 229940125364 angiotensin receptor blocker Drugs 0.000 description 4
• 239000005557 antagonist Substances 0.000 description 4
• PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
• 239000003054 catalyst Substances 0.000 description 4
• 229910052801 chlorine Inorganic materials 0.000 description 4
• 208000020832 chronic kidney disease Diseases 0.000 description 4
• 238000001816 cooling Methods 0.000 description 4
• 230000002526 effect on cardiovascular system Effects 0.000 description 4
• 230000004761 fibrosis Effects 0.000 description 4
• 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 4
• 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 4
• 238000004128 high performance liquid chromatography Methods 0.000 description 4
• 239000003112 inhibitor Substances 0.000 description 4
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
• 229910052700 potassium Inorganic materials 0.000 description 4
• 235000011056 potassium acetate Nutrition 0.000 description 4
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
• 230000002829 reductive effect Effects 0.000 description 4
• 229910052708 sodium Inorganic materials 0.000 description 4
• 229910000029 sodium carbonate Inorganic materials 0.000 description 4
• 229910000104 sodium hydride Inorganic materials 0.000 description 4
• 229910052938 sodium sulfate Inorganic materials 0.000 description 4
• 235000011152 sodium sulphate Nutrition 0.000 description 4
• VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
• 230000001225 therapeutic effect Effects 0.000 description 4
• XYMBBMUPTCSFKZ-UHFFFAOYSA-N 1,4-benzodioxine-5-carboxylic acid Chemical compound O1C=COC2=C1C=CC=C2C(=O)O XYMBBMUPTCSFKZ-UHFFFAOYSA-N 0.000 description 3
• RQMXOMCWRSEQQC-UHFFFAOYSA-N 1,4-dioxine-2-carbonitrile Chemical compound N#CC1=COC=CO1 RQMXOMCWRSEQQC-UHFFFAOYSA-N 0.000 description 3
• UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 3
• VCLSWKVAHAJSFL-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-5-carboxylic acid Chemical compound O1CCOC2=C1C=CC=C2C(=O)O VCLSWKVAHAJSFL-UHFFFAOYSA-N 0.000 description 3
• OQZDANAQIKGCEO-UHFFFAOYSA-N 2-(5-ethoxypyridin-3-yl)-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid Chemical compound C(C)OC=1C=C(C=NC=1)C1COC2=C(O1)C=CC=C2C(=O)O OQZDANAQIKGCEO-UHFFFAOYSA-N 0.000 description 3
• MXJCEZPZTXSZAN-UHFFFAOYSA-N 2-[5-(2,2,2-trifluoro-1-hydroxyethyl)pyridin-3-yl]-1,4-benzodioxine-5-carboxamide Chemical compound FC(C(O)C=1C=C(C=NC=1)C1=COC2=C(O1)C=CC=C2C(=O)N)(F)F MXJCEZPZTXSZAN-UHFFFAOYSA-N 0.000 description 3
• VMENJXMZCYDFQG-UHFFFAOYSA-N 2-[5-[2-(dimethylamino)-2-oxoethyl]pyridin-3-yl]-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical compound CN(C(CC=1C=C(C=NC=1)C1COC2=C(O1)C=CC=C2C(=O)N)=O)C VMENJXMZCYDFQG-UHFFFAOYSA-N 0.000 description 3
• IOHDYKIYBYFNDK-UHFFFAOYSA-N 4-(5-bromopyridin-3-yl)oxan-4-ol Chemical compound OC1(CCOCC1)c1cncc(Br)c1 IOHDYKIYBYFNDK-UHFFFAOYSA-N 0.000 description 3
• NGUVGKAEOFPLDT-UHFFFAOYSA-N 5-bromopyridine-3-carbaldehyde Chemical compound BrC1=CN=CC(C=O)=C1 NGUVGKAEOFPLDT-UHFFFAOYSA-N 0.000 description 3
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
• 201000001320 Atherosclerosis Diseases 0.000 description 3
• 208000016998 Conn syndrome Diseases 0.000 description 3
• OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 3
• VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 description 3
• 208000003037 Diastolic Heart Failure Diseases 0.000 description 3
• 206010018364 Glomerulonephritis Diseases 0.000 description 3
• 208000010159 IgA glomerulonephritis Diseases 0.000 description 3
• 206010021263 IgA nephropathy Diseases 0.000 description 3
• 206010049694 Left Ventricular Dysfunction Diseases 0.000 description 3
• WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
• 241000282567 Macaca fascicularis Species 0.000 description 3
• 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 3
• 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 3
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
• 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 3
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
• 208000008253 Systolic Heart Failure Diseases 0.000 description 3
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
• XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 3
• 238000007098 aminolysis reaction Methods 0.000 description 3
• 239000000908 ammonium hydroxide Substances 0.000 description 3
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
• 125000005605 benzo group Chemical group 0.000 description 3
• 125000002619 bicyclic group Chemical group 0.000 description 3
• 210000004204 blood vessel Anatomy 0.000 description 3
• 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 3
• OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 3
• ZESRJSPZRDMNHY-UHFFFAOYSA-N de-oxy corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 ZESRJSPZRDMNHY-UHFFFAOYSA-N 0.000 description 3
• 229940079593 drug Drugs 0.000 description 3
• 229910052731 fluorine Inorganic materials 0.000 description 3
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
• JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
• 235000019341 magnesium sulphate Nutrition 0.000 description 3
• 238000004949 mass spectrometry Methods 0.000 description 3
• JXAVBMJJVLXKCZ-UHFFFAOYSA-N methyl 1,4-benzodioxine-5-carboxylate Chemical compound O1C=COC2=C1C=CC=C2C(=O)OC JXAVBMJJVLXKCZ-UHFFFAOYSA-N 0.000 description 3
• 210000003470 mitochondria Anatomy 0.000 description 3
• 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
• 239000001301 oxygen Substances 0.000 description 3
• 230000037361 pathway Effects 0.000 description 3
• 239000012071 phase Substances 0.000 description 3
• 239000011591 potassium Substances 0.000 description 3
• 208000013846 primary aldosteronism Diseases 0.000 description 3
• VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 3
• 230000001105 regulatory effect Effects 0.000 description 3
• 238000000926 separation method Methods 0.000 description 3
• 239000012453 solvate Substances 0.000 description 3
• 239000011593 sulfur Chemical group 0.000 description 3
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
• KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
• UOIHFOKNQVWFRH-UHFFFAOYSA-N 1-(5-bromopyridin-3-yl)-2,2,2-trifluoroethanol Chemical compound FC(F)(F)C(O)C1=CN=CC(Br)=C1 UOIHFOKNQVWFRH-UHFFFAOYSA-N 0.000 description 2
• IBYHHJPAARCAIE-UHFFFAOYSA-N 1-bromo-2-chloroethane Chemical compound ClCCBr IBYHHJPAARCAIE-UHFFFAOYSA-N 0.000 description 2
• VMJNTFXCTXAXTC-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole-5-carbonitrile Chemical group C1=C(C#N)C=C2OC(F)(F)OC2=C1 VMJNTFXCTXAXTC-UHFFFAOYSA-N 0.000 description 2
• OBTZDIRUQWFRFZ-UHFFFAOYSA-N 2-(5-methylfuran-2-yl)-n-(4-methylphenyl)quinoline-4-carboxamide Chemical compound O1C(C)=CC=C1C1=CC(C(=O)NC=2C=CC(C)=CC=2)=C(C=CC=C2)C2=N1 OBTZDIRUQWFRFZ-UHFFFAOYSA-N 0.000 description 2
• LETRECNVFIUBQP-UHFFFAOYSA-N 2-[5-(4-hydroxyoxan-4-yl)pyridin-3-yl]-2,3-dihydro-1,4-benzodioxine-5-carbonitrile Chemical compound OC1(CCOCC1)C=1C=C(C=NC=1)C1COC2=C(O1)C=CC=C2C#N LETRECNVFIUBQP-UHFFFAOYSA-N 0.000 description 2
• HCTNTHFECVTUIV-UHFFFAOYSA-N 2-[5-(4-hydroxyoxan-4-yl)pyridin-3-yl]-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical compound OC1(CCOCC1)C=1C=C(C=NC=1)C1COC2=C(O1)C=CC=C2C(=O)N HCTNTHFECVTUIV-UHFFFAOYSA-N 0.000 description 2
• GJFMBFMZIWYEGJ-UHFFFAOYSA-N 2-[5-(aminomethyl)pyridin-3-yl]-2,3-dihydro-1,4-benzodioxine-5-carbonitrile Chemical compound NCC=1C=C(C=NC=1)C1COC2=C(O1)C=CC=C2C#N GJFMBFMZIWYEGJ-UHFFFAOYSA-N 0.000 description 2
• JQODTJVNGPAMJY-UHFFFAOYSA-N 2-[5-[(2-oxo-1,3-oxazolidin-3-yl)methyl]pyridin-3-yl]-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical compound O=C1OCCN1CC=1C=C(C=NC=1)C1COC2=C(O1)C=CC=C2C(=O)N JQODTJVNGPAMJY-UHFFFAOYSA-N 0.000 description 2
• OFSUERQQKPWSRR-UHFFFAOYSA-N 2-[5-[2-(dimethylamino)-2-oxoethyl]pyridin-3-yl]-1,4-benzodioxine-5-carboxamide Chemical compound CN(C(CC=1C=C(C=NC=1)C1=COC2=C(O1)C=CC=C2C(=O)N)=O)C OFSUERQQKPWSRR-UHFFFAOYSA-N 0.000 description 2
• DIXJYCNLZCNAAJ-UHFFFAOYSA-N 2-bromo-N-methyl-1,4-benzodioxine-5-carboxamide Chemical compound CNC(=O)C1=CC=CC=2OC(=COC=21)Br DIXJYCNLZCNAAJ-UHFFFAOYSA-N 0.000 description 2
• LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 2
• YBTCTFGHRSGZLE-UHFFFAOYSA-N 3,3-dibromo-5-(5-bromopyridin-3-yl)pyrrolidin-2-one Chemical compound Brc1cncc(c1)C1CC(Br)(Br)C(=O)N1 YBTCTFGHRSGZLE-UHFFFAOYSA-N 0.000 description 2
• SOSPMXMEOFGPIM-UHFFFAOYSA-N 3,5-dibromopyridine Chemical compound BrC1=CN=CC(Br)=C1 SOSPMXMEOFGPIM-UHFFFAOYSA-N 0.000 description 2
• RXQSDYZMUBXBAI-UHFFFAOYSA-N 3-bromo-5-(methylsulfanylmethoxy)pyridine Chemical compound BrC=1C=NC=C(C=1)OCSC RXQSDYZMUBXBAI-UHFFFAOYSA-N 0.000 description 2
• HNNNBQRRIHKFLI-UHFFFAOYSA-N 3-bromo-5-fluoropyridine Chemical compound FC1=CN=CC(Br)=C1 HNNNBQRRIHKFLI-UHFFFAOYSA-N 0.000 description 2
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
• FHFLWXYVJTXTSS-UHFFFAOYSA-N 4-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl]oxan-4-ol Chemical compound CC1(C)OB(OC1(C)C)c1cncc(c1)C1(O)CCOCC1 FHFLWXYVJTXTSS-UHFFFAOYSA-N 0.000 description 2
• WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 2
• NJWBNFSXZZLYMG-UHFFFAOYSA-N 4-bromo-5,6-dihydrocyclopenta[c]pyridin-7-one Chemical compound BrC1=CN=CC2=C1CCC2=O NJWBNFSXZZLYMG-UHFFFAOYSA-N 0.000 description 2
• SZEOJTCTXPPVLM-UHFFFAOYSA-N 4-bromo-6,7-dihydro-5h-cyclopenta[c]pyridin-7-ol Chemical compound C1=NC=C(Br)C2=C1C(O)CC2 SZEOJTCTXPPVLM-UHFFFAOYSA-N 0.000 description 2
• CIYMLLDCIBUVKR-UHFFFAOYSA-N 5-(3,6-dihydro-2H-pyran-4-yl)pyridin-3-ol Chemical compound O1CCC(=CC1)C=1C=C(C=NC=1)O CIYMLLDCIBUVKR-UHFFFAOYSA-N 0.000 description 2
• XXOGLRABMPUQAT-UHFFFAOYSA-N 5-(oxan-4-yl)pyridin-3-ol Chemical compound O1CCC(CC1)C=1C=C(C=NC=1)O XXOGLRABMPUQAT-UHFFFAOYSA-N 0.000 description 2
• NEMOGJGTCATZAO-UHFFFAOYSA-N 5-bromo-4-methylpyridine-3-carboxamide Chemical compound CC1=C(Br)C=NC=C1C(N)=O NEMOGJGTCATZAO-UHFFFAOYSA-N 0.000 description 2
• 239000005541 ACE inhibitor Substances 0.000 description 2
• 108091006112 ATPases Proteins 0.000 description 2
• 102000057290 Adenosine Triphosphatases Human genes 0.000 description 2
• 102000005862 Angiotensin II Human genes 0.000 description 2
• 101800000733 Angiotensin-2 Proteins 0.000 description 2
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
• MLPWNIOPJLWCFP-UHFFFAOYSA-N C1(CC1)CCS(=O)(=O)NCC=1C=C(C=NC=1)C1=COC2=C(O1)C=CC=C2C(=O)N Chemical compound C1(CC1)CCS(=O)(=O)NCC=1C=C(C=NC=1)C1=COC2=C(O1)C=CC=C2C(=O)N MLPWNIOPJLWCFP-UHFFFAOYSA-N 0.000 description 2
• 239000004215 Carbon black (E152) Substances 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
• 208000008448 Congenital adrenal hyperplasia Diseases 0.000 description 2
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
• BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
• FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
• 206010065673 Nephritic syndrome Diseases 0.000 description 2
• AKLDMJUOVDADRM-UHFFFAOYSA-N OCC=1C=C(C=NC=1)C1COC2=C(O1)C=CC=C2C(=O)O Chemical compound OCC=1C=C(C=NC=1)C1COC2=C(O1)C=CC=C2C(=O)O AKLDMJUOVDADRM-UHFFFAOYSA-N 0.000 description 2
• RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
• WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
• 238000006069 Suzuki reaction reaction Methods 0.000 description 2
• RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
• OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
• SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 230000005856 abnormality Effects 0.000 description 2
• XBJFCYDKBDVADW-UHFFFAOYSA-N acetonitrile;formic acid Chemical compound CC#N.OC=O XBJFCYDKBDVADW-UHFFFAOYSA-N 0.000 description 2
• WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
• 239000012346 acetyl chloride Substances 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 125000002015 acyclic group Chemical group 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• 229910052782 aluminium Inorganic materials 0.000 description 2
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
• 239000002333 angiotensin II receptor antagonist Substances 0.000 description 2
• 229950006323 angiotensin ii Drugs 0.000 description 2
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
• 239000012298 atmosphere Substances 0.000 description 2
• RPHLNRIJHROTSF-UHFFFAOYSA-N azanium;acetonitrile;hydrogen carbonate Chemical compound [NH4+].CC#N.OC([O-])=O RPHLNRIJHROTSF-UHFFFAOYSA-N 0.000 description 2
• HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 2
• 230000036772 blood pressure Effects 0.000 description 2
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
• 229910052794 bromium Inorganic materials 0.000 description 2
• INLLPKCGLOXCIV-UHFFFAOYSA-N bromoethene Chemical compound BrC=C INLLPKCGLOXCIV-UHFFFAOYSA-N 0.000 description 2
• 235000011089 carbon dioxide Nutrition 0.000 description 2
• KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 2
• 238000004440 column chromatography Methods 0.000 description 2
• 238000002648 combination therapy Methods 0.000 description 2
• 229940127271 compound 49 Drugs 0.000 description 2
• 239000013058 crude material Substances 0.000 description 2
• JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
• YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 2
• CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
• 229940043279 diisopropylamine Drugs 0.000 description 2
• 239000006185 dispersion Substances 0.000 description 2
• 150000002148 esters Chemical class 0.000 description 2
• ZCRZCMUDOWDGOB-UHFFFAOYSA-N ethanesulfonimidic acid Chemical compound CCS(N)(=O)=O ZCRZCMUDOWDGOB-UHFFFAOYSA-N 0.000 description 2
• PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 2
• 230000003176 fibrotic effect Effects 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 239000011737 fluorine Substances 0.000 description 2
• 230000001434 glomerular Effects 0.000 description 2
• 230000024924 glomerular filtration Effects 0.000 description 2
• 238000010438 heat treatment Methods 0.000 description 2
• 229940088597 hormone Drugs 0.000 description 2
• 239000005556 hormone Substances 0.000 description 2
• 229930195733 hydrocarbon Natural products 0.000 description 2
• 229910052740 iodine Inorganic materials 0.000 description 2
• 150000002500 ions Chemical class 0.000 description 2
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• 208000017169 kidney disease Diseases 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
• 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 2
• GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
• 230000014759 maintenance of location Effects 0.000 description 2
• 239000002207 metabolite Substances 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• HLHQUYAWGSTFBN-UHFFFAOYSA-N methyl 2,3-dibromo-2,3-dihydro-1,4-benzodioxine-5-carboxylate Chemical compound COC(=O)C1=CC=CC=2OC(C(OC=21)Br)Br HLHQUYAWGSTFBN-UHFFFAOYSA-N 0.000 description 2
• ZPKXULSJPDNOJY-UHFFFAOYSA-N methyl 2,3-dihydro-1,4-benzodioxine-5-carboxylate Chemical compound O1CCOC2=C1C=CC=C2C(=O)OC ZPKXULSJPDNOJY-UHFFFAOYSA-N 0.000 description 2
• HPMQJWKQKSBNLU-UHFFFAOYSA-N methyl 2-(5-cyano-4-methylpyridin-3-yl)-2,3-dihydro-1,4-benzodioxine-5-carboxylate Chemical compound COC(=O)C1=CC=CC=2OC(COC=21)C=1C=NC=C(C=1C)C#N HPMQJWKQKSBNLU-UHFFFAOYSA-N 0.000 description 2
• ZAVBUTQEBKJTAT-UHFFFAOYSA-N methyl 2-(5-phenylmethoxypyridin-3-yl)-1,4-benzodioxine-5-carboxylate Chemical compound COC(=O)C1=CC=CC=2OC(=COC=21)C=1C=NC=C(C=1)OCC1=CC=CC=C1 ZAVBUTQEBKJTAT-UHFFFAOYSA-N 0.000 description 2
• SGWFETCOJSSRAH-UHFFFAOYSA-N methyl 2-(5-piperidin-4-yloxypyridin-3-yl)-2,3-dihydro-1,4-benzodioxine-5-carboxylate Chemical compound COC(=O)C1=CC=CC=2OC(COC=21)C=1C=NC=C(C=1)OC1CCNCC1 SGWFETCOJSSRAH-UHFFFAOYSA-N 0.000 description 2
• 208000038001 non-diabetic kidney disease Diseases 0.000 description 2
• 239000012074 organic phase Substances 0.000 description 2
• PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
• 229910000027 potassium carbonate Inorganic materials 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 238000002360 preparation method Methods 0.000 description 2
• 230000002206 pro-fibrotic effect Effects 0.000 description 2
• 230000000770 proinflammatory effect Effects 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 238000010898 silica gel chromatography Methods 0.000 description 2
• 229910000033 sodium borohydride Inorganic materials 0.000 description 2
• 239000012279 sodium borohydride Substances 0.000 description 2
• 239000012312 sodium hydride Substances 0.000 description 2
• 239000007858 starting material Substances 0.000 description 2
• SRRRGKBYWYPHPM-UHFFFAOYSA-N tert-butyl 4-[5-(5-methoxycarbonyl-2,3-dihydro-1,4-benzodioxin-2-yl)pyridin-3-yl]oxypiperidine-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)OC=1C=NC=C(C=1)C1COC2=C(O1)C=CC=C2C(=O)OC SRRRGKBYWYPHPM-UHFFFAOYSA-N 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 238000004809 thin layer chromatography Methods 0.000 description 2
• 125000003396 thiol group Chemical group [H]S* 0.000 description 2
• KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 2
• WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
• 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 2
• LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
• 230000002792 vascular Effects 0.000 description 2
• UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
• YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
• HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
• MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
• OQUHYNMITHDQLD-UHFFFAOYSA-N (5-bromopyridin-3-yl)methanamine Chemical compound NCC1=CN=CC(Br)=C1 OQUHYNMITHDQLD-UHFFFAOYSA-N 0.000 description 1
• 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
• KFHHPVVJLXPHJL-UPHRSURJSA-N (z)-4-hydroperoxy-4-oxobut-2-enoic acid Chemical class OOC(=O)\C=C/C(O)=O KFHHPVVJLXPHJL-UPHRSURJSA-N 0.000 description 1
• DJMOXMNDXFFONV-UHFFFAOYSA-N 1,3-dimethyl-7-[2-(n-methylanilino)ethyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCN(C)C1=CC=CC=C1 DJMOXMNDXFFONV-UHFFFAOYSA-N 0.000 description 1
• KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
• MBMHYJKXOQVMPF-UHFFFAOYSA-N 1,4-benzodioxine-5-carbonitrile Chemical compound O1C=COC2=C1C=CC=C2C#N MBMHYJKXOQVMPF-UHFFFAOYSA-N 0.000 description 1
• WHOZDLQKWBNXOC-UHFFFAOYSA-N 1,4-dioxine-2-carboxamide Chemical compound NC(=O)C1=COC=CO1 WHOZDLQKWBNXOC-UHFFFAOYSA-N 0.000 description 1
• LXASMIMMLISWQV-UHFFFAOYSA-N 1-(5-bromo-4-methylpyridin-3-yl)ethanol Chemical compound CC(O)C1=CN=CC(Br)=C1C LXASMIMMLISWQV-UHFFFAOYSA-N 0.000 description 1
• JTHYIBDRZVYQMK-UHFFFAOYSA-N 1-(5-bromopyridin-3-yl)cyclohexan-1-ol Chemical compound BrC=1C=C(C=NC=1)C1(CCCCC1)O JTHYIBDRZVYQMK-UHFFFAOYSA-N 0.000 description 1
• IQQZIJPWEAFLNT-UHFFFAOYSA-N 1-(5-bromopyridin-3-yl)cyclopropane-1-carbonitrile Chemical compound BrC1=CN=CC(C2(CC2)C#N)=C1 IQQZIJPWEAFLNT-UHFFFAOYSA-N 0.000 description 1
• DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 1
• KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
• SRWSKQFHCXMKEA-UHFFFAOYSA-N 1-[(5-bromopyridin-3-yl)methyl]pyrrolidin-2-one Chemical compound BrC1=CN=CC(CN2C(CCC2)=O)=C1 SRWSKQFHCXMKEA-UHFFFAOYSA-N 0.000 description 1
• ZOKCLPSQEMETMI-UHFFFAOYSA-N 1-[4-(5-bromopyridin-3-yl)oxypiperidin-1-yl]ethanone Chemical compound CC(=O)N1CCC(CC1)Oc1cncc(Br)c1 ZOKCLPSQEMETMI-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• WHBHBVVOGNECLV-UHFFFAOYSA-N 11-deoxy-17-hydroxy-corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 WHBHBVVOGNECLV-UHFFFAOYSA-N 0.000 description 1
• WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 description 1
• HFSXHZZDNDGLQN-ZVIOFETBSA-N 18-hydroxycorticosterone Chemical compound C([C@]1(CO)[C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 HFSXHZZDNDGLQN-ZVIOFETBSA-N 0.000 description 1
• YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
• NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 1
• DOSGEBYQRMBTGS-UHFFFAOYSA-N 2-(3,6-dihydro-2h-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CCOCC1 DOSGEBYQRMBTGS-UHFFFAOYSA-N 0.000 description 1
• HOUIODDHRUJQPR-UHFFFAOYSA-N 2-(4-acetyl-5-fluoropyridin-3-yl)-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical class C(C)(=O)C1=C(C=NC=C1F)C1COC2=C(O1)C=CC=C2C(=O)N HOUIODDHRUJQPR-UHFFFAOYSA-N 0.000 description 1
• XUJNDEOMVGNBTA-UHFFFAOYSA-N 2-(4-methylpyridin-3-yl)-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical compound CC1=C(C=NC=C1)C1COC2=C(O1)C=CC=C2C(=O)N XUJNDEOMVGNBTA-UHFFFAOYSA-N 0.000 description 1
• MEMYGOGHVUPQCP-UHFFFAOYSA-N 2-(5-bromopyridin-3-yl)-1-(4,4-difluoropiperidin-1-yl)ethanone Chemical compound BrC=1C=C(C=NC=1)CC(=O)N1CCC(CC1)(F)F MEMYGOGHVUPQCP-UHFFFAOYSA-N 0.000 description 1
• FEYPEIBUEKDVNO-UHFFFAOYSA-N 2-(5-bromopyridin-3-yl)-1-morpholin-4-ylethanone Chemical compound BrC1=CN=CC(CC(=O)N2CCOCC2)=C1 FEYPEIBUEKDVNO-UHFFFAOYSA-N 0.000 description 1
• NGSJXAQHUJFHEF-UHFFFAOYSA-N 2-(5-bromopyridin-3-yl)acetonitrile Chemical compound BrC1=CN=CC(CC#N)=C1 NGSJXAQHUJFHEF-UHFFFAOYSA-N 0.000 description 1
• PNMADGPAHJEPGI-UHFFFAOYSA-N 2-(5-cyano-4-methylpyridin-3-yl)-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical compound C(#N)C=1C(=C(C=NC=1)C1COC2=C(O1)C=CC=C2C(=O)N)C PNMADGPAHJEPGI-UHFFFAOYSA-N 0.000 description 1
• GHGHMOSUGSGJDI-UHFFFAOYSA-N 2-(5-fluoropyridin-3-yl)-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical compound FC=1C=C(C=NC=1)C1COC2=C(O1)C=CC=C2C(=O)N GHGHMOSUGSGJDI-UHFFFAOYSA-N 0.000 description 1
• DHUZGEUTRJOXQP-UHFFFAOYSA-N 2-(5-methylpyridin-3-yl)-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical compound CC=1C=C(C=NC=1)C1COC2=C(O1)C=CC=C2C(=O)N DHUZGEUTRJOXQP-UHFFFAOYSA-N 0.000 description 1
• GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
• IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
• HGCIJLVDAXFQHH-UHFFFAOYSA-N 2-[(5-bromopyridin-3-yl)methyl]thiazinane 1,1-dioxide Chemical compound BrC1=CN=CC(CN2S(CCCC2)(=O)=O)=C1 HGCIJLVDAXFQHH-UHFFFAOYSA-N 0.000 description 1
• SDFISFSUSFGLOU-UHFFFAOYSA-N 2-[5-(1-acetylazetidin-3-yl)oxypyridin-3-yl]-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical compound C(C)(=O)N1CC(C1)OC=1C=C(C=NC=1)C1COC2=C(O1)C=CC=C2C(=O)N SDFISFSUSFGLOU-UHFFFAOYSA-N 0.000 description 1
• QNLRNSJDBOSNOJ-UHFFFAOYSA-N 2-[5-(1-acetylpiperidin-4-yl)oxypyridin-3-yl]-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical compound C(C)(=O)N1CCC(CC1)OC=1C=C(C=NC=1)C1COC2=C(O1)C=CC=C2C(=O)N QNLRNSJDBOSNOJ-UHFFFAOYSA-N 0.000 description 1
• DEPJHVDEYDKNKU-UHFFFAOYSA-N 2-[5-(1-acetylpiperidin-4-yl)oxypyridin-3-yl]-N-methyl-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical compound CNC(=O)C1=CC=CC=2OC(COC=21)C=1C=NC=C(C=1)OC1CCN(CC1)C(C)=O DEPJHVDEYDKNKU-UHFFFAOYSA-N 0.000 description 1
• VYPVUOCQMOVGPE-UHFFFAOYSA-N 2-[5-(1-hydroxycyclobutyl)pyridin-3-yl]-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical compound OC1(CCC1)C=1C=C(C=NC=1)C1COC2=C(O1)C=CC=C2C(=O)N VYPVUOCQMOVGPE-UHFFFAOYSA-N 0.000 description 1
• KHGSHGUBXMIAGY-UHFFFAOYSA-N 2-[5-(1-hydroxycyclohexyl)pyridin-3-yl]-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical compound OC1(CCCCC1)C=1C=C(C=NC=1)C1COC2=C(O1)C=CC=C2C(=O)N KHGSHGUBXMIAGY-UHFFFAOYSA-N 0.000 description 1
• CLKSBAGKMOBJOZ-UHFFFAOYSA-N 2-[5-(1-methyl-5-oxopyrrolidin-2-yl)pyridin-3-yl]-2,3-dihydro-1,4-benzodioxine-5-carbonitrile Chemical compound CN1C(CCC1=O)C=1C=C(C=NC=1)C1COC2=C(O1)C=CC=C2C#N CLKSBAGKMOBJOZ-UHFFFAOYSA-N 0.000 description 1
• RTMHPDMWIWHSCO-UHFFFAOYSA-N 2-[5-(2,2,2-trifluoro-1-hydroxyethyl)pyridin-3-yl]-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical compound FC(C(O)C=1C=C(C=NC=1)C1COC2=C(O1)C=CC=C2C(=O)N)(F)F RTMHPDMWIWHSCO-UHFFFAOYSA-N 0.000 description 1
• VASJXZYJWXSLSN-UHFFFAOYSA-N 2-[5-(2-morpholin-4-yl-2-oxoethyl)pyridin-3-yl]-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical compound N1(CCOCC1)C(CC=1C=C(C=NC=1)C1COC2=C(O1)C=CC=C2C(=O)N)=O VASJXZYJWXSLSN-UHFFFAOYSA-N 0.000 description 1
• MGANNCDWEKCVMV-UHFFFAOYSA-N 2-[5-(bromomethyl)pyridin-3-yl]-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid Chemical compound BrCC=1C=C(C=NC=1)C1COC2=C(O1)C=CC=C2C(=O)O MGANNCDWEKCVMV-UHFFFAOYSA-N 0.000 description 1
• AMTHMYBVMPXPNY-UHFFFAOYSA-N 2-[5-(difluoromethyl)pyridin-3-yl]-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical compound NC(=O)C1=CC=CC2=C1OCC(O2)C1=CN=CC(=C1)C(F)F AMTHMYBVMPXPNY-UHFFFAOYSA-N 0.000 description 1
• KOIFEFDOLBSZKR-UHFFFAOYSA-N 2-[5-(methylsulfonylmethyl)pyridin-3-yl]-2,3-dihydro-1,4-benzodioxine-5-carbonitrile Chemical compound CS(=O)(=O)CC=1C=C(C=NC=1)C1COC2=C(O1)C=CC=C2C#N KOIFEFDOLBSZKR-UHFFFAOYSA-N 0.000 description 1
• CTKRUEJKWHENOZ-UHFFFAOYSA-N 2-[5-(oxan-4-yloxy)pyridin-3-yl]-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical compound O1CCC(CC1)OC=1C=C(C=NC=1)C1COC2=C(O1)C=CC=C2C(=O)N CTKRUEJKWHENOZ-UHFFFAOYSA-N 0.000 description 1
• MASSNAHEORWXHG-UHFFFAOYSA-N 2-[5-(trifluoromethyl)pyridin-3-yl]-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical compound FC(C=1C=C(C=NC=1)C1COC2=C(O1)C=CC=C2C(=O)N)(F)F MASSNAHEORWXHG-UHFFFAOYSA-N 0.000 description 1
• WTIUFKDXWDUKHL-UHFFFAOYSA-N 2-[5-[(1,1-dioxothiazinan-2-yl)methyl]pyridin-3-yl]-2,3-dihydro-1,4-benzodioxine-5-carbonitrile Chemical compound O=S1(N(CCCC1)CC=1C=C(C=NC=1)C1COC2=C(O1)C=CC=C2C#N)=O WTIUFKDXWDUKHL-UHFFFAOYSA-N 0.000 description 1
• HVXOUEINAHIAGH-UHFFFAOYSA-N 2-[5-[(3-oxomorpholin-4-yl)methyl]pyridin-3-yl]-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical compound O=C1N(CCOC1)CC=1C=C(C=NC=1)C1COC2=C(O1)C=CC=C2C(=O)N HVXOUEINAHIAGH-UHFFFAOYSA-N 0.000 description 1
• XDLPZKPRNVWBMB-PIVQAISJSA-N 2-[5-[(3S)-1-acetylpyrrolidin-3-yl]oxypyridin-3-yl]-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical compound C(C)(=O)N1C[C@H](CC1)OC=1C=C(C=NC=1)C1COC2=C(O1)C=CC=C2C(=O)N XDLPZKPRNVWBMB-PIVQAISJSA-N 0.000 description 1
• SLGUYDWINFZCRR-UHFFFAOYSA-N 2-[5-[(cyclopropanecarbonylamino)methyl]pyridin-3-yl]-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical compound C1(CC1)C(=O)NCC=1C=C(C=NC=1)C1COC2=C(O1)C=CC=C2C(=O)N SLGUYDWINFZCRR-UHFFFAOYSA-N 0.000 description 1
• TYOCMPNBWVXUMN-UHFFFAOYSA-N 2-[5-[[2-(dimethylamino)-2-oxoethoxy]methyl]pyridin-3-yl]-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical compound CN(C(=O)COCC=1C=C(C=NC=1)C1COC2=C(O1)C=CC=C2C(=O)N)C TYOCMPNBWVXUMN-UHFFFAOYSA-N 0.000 description 1
• VOKHEFXJSZWKIP-UHFFFAOYSA-N 2-[5-[cyclopropyl-(ethylsulfonylamino)methyl]pyridin-3-yl]-1,4-benzodioxine-5-carboxamide Chemical compound C1(CC1)C(C=1C=C(C=NC=1)C1=COC2=C(O1)C=CC=C2C(=O)N)NS(=O)(=O)CC VOKHEFXJSZWKIP-UHFFFAOYSA-N 0.000 description 1
• UNQIOQROCZZZHI-UHFFFAOYSA-N 2-[5-fluoro-4-(1-hydroxyethyl)pyridin-3-yl]-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical compound FC=1C(=C(C=NC=1)C1COC2=C(O1)C=CC=C2C(=O)N)C(C)O UNQIOQROCZZZHI-UHFFFAOYSA-N 0.000 description 1
• DVRNDLPLWZDBLV-UHFFFAOYSA-N 2-[5-fluoro-4-(2-hydroxypropan-2-yl)pyridin-3-yl]-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical compound FC=1C(=C(C=NC=1)C1COC2=C(O1)C=CC=C2C(=O)N)C(C)(C)O DVRNDLPLWZDBLV-UHFFFAOYSA-N 0.000 description 1
• PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
• FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
• ULQQGOGMQRGFFR-UHFFFAOYSA-N 2-chlorobenzenecarboperoxoic acid Chemical compound OOC(=O)C1=CC=CC=C1Cl ULQQGOGMQRGFFR-UHFFFAOYSA-N 0.000 description 1
• IUKSYUOJRHDWRR-UHFFFAOYSA-N 2-diazonio-4,6-dinitrophenolate Chemical compound [O-]C1=C([N+]#N)C=C([N+]([O-])=O)C=C1[N+]([O-])=O IUKSYUOJRHDWRR-UHFFFAOYSA-N 0.000 description 1
• DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 1
• RTPJEGRWQULDTD-UHFFFAOYSA-N 2-pyridin-3-yl-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical compound N1=CC(=CC=C1)C1COC2=C(O1)C=CC=C2C(=O)N RTPJEGRWQULDTD-UHFFFAOYSA-N 0.000 description 1
• BNCGUATWCKZLLN-UHFFFAOYSA-N 3,5-dibromo-4-methylpyridine Chemical compound CC1=C(Br)C=NC=C1Br BNCGUATWCKZLLN-UHFFFAOYSA-N 0.000 description 1
• DMBKVOYJOGETRJ-UHFFFAOYSA-N 3-(methylsulfanylmethyl)pyridine Chemical compound CSCC1=CC=CN=C1 DMBKVOYJOGETRJ-UHFFFAOYSA-N 0.000 description 1
• UBEURKGBJZLGEQ-UHFFFAOYSA-N 3-[(5-bromopyridin-3-yl)methyl]-1,3-oxazolidin-2-one Chemical compound BrC=1C=C(C=NC=1)CN1C(OCC1)=O UBEURKGBJZLGEQ-UHFFFAOYSA-N 0.000 description 1
• LEQDBJVFYDLMTK-UHFFFAOYSA-N 3-bromo-5-(4-fluorooxan-4-yl)pyridine Chemical compound BrC=1C=NC=C(C=1)C1(CCOCC1)F LEQDBJVFYDLMTK-UHFFFAOYSA-N 0.000 description 1
• YEIYXHOMHKPBGQ-UHFFFAOYSA-N 3-bromo-5-(difluoromethyl)pyridine Chemical compound FC(F)C1=CN=CC(Br)=C1 YEIYXHOMHKPBGQ-UHFFFAOYSA-N 0.000 description 1
• GQEYXBXLVQIEAM-UHFFFAOYSA-N 3-bromo-5-(methylsulfonylmethoxy)pyridine Chemical compound BrC=1C=NC=C(C=1)OCS(=O)(=O)C GQEYXBXLVQIEAM-UHFFFAOYSA-N 0.000 description 1
• LFAMWMZRCCAILY-UHFFFAOYSA-N 3-bromo-5-(methylsulfonylmethyl)pyridine Chemical compound CS(=O)(=O)CC1=CN=CC(Br)=C1 LFAMWMZRCCAILY-UHFFFAOYSA-N 0.000 description 1
• XLELTAPOTWVYLE-UHFFFAOYSA-N 3-bromo-5-fluoro-4-methylpyridine Chemical compound CC1=C(F)C=NC=C1Br XLELTAPOTWVYLE-UHFFFAOYSA-N 0.000 description 1
• YSHKYZAWTWKQKK-UHFFFAOYSA-N 3-bromo-5-phenylmethoxypyridine Chemical compound BrC1=CN=CC(OCC=2C=CC=CC=2)=C1 YSHKYZAWTWKQKK-UHFFFAOYSA-N 0.000 description 1
• APOQHGHGEPQGOO-UHFFFAOYSA-N 3-bromo-5-pyrrolidin-2-ylpyridine Chemical compound BrC1=CN=CC(C2NCCC2)=C1 APOQHGHGEPQGOO-UHFFFAOYSA-N 0.000 description 1
• NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
• MUQCREWUJVGVQL-UHFFFAOYSA-N 4-(5-bromopyridin-3-yl)benzenesulfonamide Chemical compound BrC=1C=C(C=NC=1)C1=CC=C(C=C1)S(=O)(=O)N MUQCREWUJVGVQL-UHFFFAOYSA-N 0.000 description 1
• 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
• 125000001054 5 membered carbocyclic group Chemical group 0.000 description 1
• XZLVBNOMLBQYEE-UHFFFAOYSA-N 5-(5-bromopyridin-3-yl)-1-methylpyrrolidin-2-one Chemical compound C1CC(=O)N(C)C1C1=CN=CC(Br)=C1 XZLVBNOMLBQYEE-UHFFFAOYSA-N 0.000 description 1
• ASQYHAFTYONKOX-UHFFFAOYSA-N 5-(5-bromopyridin-3-yl)pyrrolidin-2-one Chemical compound Brc1cncc(c1)C1CCC(=O)N1 ASQYHAFTYONKOX-UHFFFAOYSA-N 0.000 description 1
• RLENEIYXKWSGEX-UHFFFAOYSA-N 5-bromo-4-methylpyridine-3-carboxylic acid Chemical compound CC1=C(Br)C=NC=C1C(O)=O RLENEIYXKWSGEX-UHFFFAOYSA-N 0.000 description 1
• XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
• 125000004008 6 membered carbocyclic group Chemical group 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
• 206010001580 Albuminuria Diseases 0.000 description 1
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 102000008873 Angiotensin II receptor Human genes 0.000 description 1
• 108050000824 Angiotensin II receptor Proteins 0.000 description 1
• KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• PWFCKURRYWPOAK-UHFFFAOYSA-N C(C)(=O)C1=C(C=NC=C1F)C1COC2=C(O1)C=CC=C2C(=O)O Chemical compound C(C)(=O)C1=C(C=NC=C1F)C1COC2=C(O1)C=CC=C2C(=O)O PWFCKURRYWPOAK-UHFFFAOYSA-N 0.000 description 1
• ISMDILRWKSYCOD-GNKBHMEESA-N C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O Chemical compound C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O ISMDILRWKSYCOD-GNKBHMEESA-N 0.000 description 1
• YXBCNEAWJSBEOO-UHFFFAOYSA-N CC1=C(C=NC=C1C#N)C2COC3=C(C=CC=C3O2)C(=O)O Chemical compound CC1=C(C=NC=C1C#N)C2COC3=C(C=CC=C3O2)C(=O)O YXBCNEAWJSBEOO-UHFFFAOYSA-N 0.000 description 1
• NRSKLCCINAQQQL-UHFFFAOYSA-N CCN(CC)S.F.F.F Chemical compound CCN(CC)S.F.F.F NRSKLCCINAQQQL-UHFFFAOYSA-N 0.000 description 1
• COKRFBWEDOWVFX-UHFFFAOYSA-N CN.C1(CC1)C(=O)O Chemical compound CN.C1(CC1)C(=O)O COKRFBWEDOWVFX-UHFFFAOYSA-N 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
• 208000006029 Cardiomegaly Diseases 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 101150065749 Churc1 gene Proteins 0.000 description 1
• 229940126639 Compound 33 Drugs 0.000 description 1
• 102400000739 Corticotropin Human genes 0.000 description 1
• 101800000414 Corticotropin Proteins 0.000 description 1
• 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
• LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 206010048554 Endothelial dysfunction Diseases 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
• 239000007821 HATU Substances 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• 108091006671 Ion Transporter Proteins 0.000 description 1
• 102000037862 Ion Transporter Human genes 0.000 description 1
• 150000000994 L-ascorbates Chemical class 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
• 206010029164 Nephrotic syndrome Diseases 0.000 description 1
• 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
• 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
• YDMFGYRPOABBMF-UHFFFAOYSA-N OC=1C=C(C=NC1)C1COC2=C(O1)C=CC=C2C(=O)O Chemical compound OC=1C=C(C=NC1)C1COC2=C(O1)C=CC=C2C(=O)O YDMFGYRPOABBMF-UHFFFAOYSA-N 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
• 102100038239 Protein Churchill Human genes 0.000 description 1
• 206010038468 Renal hypertrophy Diseases 0.000 description 1
• 102100028255 Renin Human genes 0.000 description 1
• 108090000783 Renin Proteins 0.000 description 1
• 229910006074 SO2NH2 Inorganic materials 0.000 description 1
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
• 239000012317 TBTU Substances 0.000 description 1
• 229920002253 Tannate Polymers 0.000 description 1
• 108010046377 Whey Proteins Proteins 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
• PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
• SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
• ZBIKORITPGTTGI-UHFFFAOYSA-N [acetyloxy(phenyl)-$l^{3}-iodanyl] acetate Chemical compound CC(=O)OI(OC(C)=O)C1=CC=CC=C1 ZBIKORITPGTTGI-UHFFFAOYSA-N 0.000 description 1
• CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• 150000008043 acidic salts Chemical class 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 125000002252 acyl group Chemical group 0.000 description 1
• 210000001789 adipocyte Anatomy 0.000 description 1
• 238000011360 adjunctive therapy Methods 0.000 description 1
• 238000009098 adjuvant therapy Methods 0.000 description 1
• 230000001919 adrenal effect Effects 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
• 150000001447 alkali salts Chemical class 0.000 description 1
• 125000003342 alkenyl group Chemical group 0.000 description 1
• 125000003545 alkoxy group Chemical group 0.000 description 1
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
• 125000002947 alkylene group Chemical group 0.000 description 1
• 125000000304 alkynyl group Chemical group 0.000 description 1
• PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
• CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
• 229940063655 aluminum stearate Drugs 0.000 description 1
• 125000003368 amide group Chemical group 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 235000019270 ammonium chloride Nutrition 0.000 description 1
• 125000000129 anionic group Chemical group 0.000 description 1
• 230000008485 antagonism Effects 0.000 description 1
• 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• 208000037849 arterial hypertension Diseases 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
• 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
• 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• LISGWWQJIMNQTP-UHFFFAOYSA-N boranyloxyborane Chemical compound BOB LISGWWQJIMNQTP-UHFFFAOYSA-N 0.000 description 1
• 150000001649 bromium compounds Chemical class 0.000 description 1
• GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical class BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 1
• 230000005587 bubbling Effects 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 230000008777 canonical pathway Effects 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 150000001735 carboxylic acids Chemical class 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 238000005341 cation exchange Methods 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 239000003795 chemical substances by application Substances 0.000 description 1
• 150000001805 chlorine compounds Chemical class 0.000 description 1
• JWMLCCRPDOIBAV-UHFFFAOYSA-N chloro(methylsulfanyl)methane Chemical compound CSCCl JWMLCCRPDOIBAV-UHFFFAOYSA-N 0.000 description 1
• 230000007881 chronic fibrosis Effects 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 230000006020 chronic inflammation Effects 0.000 description 1
• 150000001860 citric acid derivatives Chemical class 0.000 description 1
• 229940125904 compound 1 Drugs 0.000 description 1
• 229940125782 compound 2 Drugs 0.000 description 1
• 229940127204 compound 29 Drugs 0.000 description 1
• 229940126214 compound 3 Drugs 0.000 description 1
• 229940125877 compound 31 Drugs 0.000 description 1
• 229940126545 compound 53 Drugs 0.000 description 1
• 229940127113 compound 57 Drugs 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
• 229960000258 corticotropin Drugs 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 229940119740 deoxycorticosterone Drugs 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
• AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• KJOZJSGOIJQCGA-UHFFFAOYSA-N dichloromethane;2,2,2-trifluoroacetic acid Chemical compound ClCCl.OC(=O)C(F)(F)F KJOZJSGOIJQCGA-UHFFFAOYSA-N 0.000 description 1
• 125000005046 dihydronaphthyl group Chemical group 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• 125000000532 dioxanyl group Chemical group 0.000 description 1
• 239000001177 diphosphate Substances 0.000 description 1
• XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical class [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
• 235000011180 diphosphates Nutrition 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 229940048820 edetates Drugs 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 210000000750 endocrine system Anatomy 0.000 description 1
• 230000008694 endothelial dysfunction Effects 0.000 description 1
• AFAXGSQYZLGZPG-UHFFFAOYSA-L ethanedisulfonate group Chemical class C(CS(=O)(=O)[O-])S(=O)(=O)[O-] AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• FRYHCSODNHYDPU-UHFFFAOYSA-N ethanesulfonyl chloride Chemical compound CCS(Cl)(=O)=O FRYHCSODNHYDPU-UHFFFAOYSA-N 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 239000011888 foil Substances 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 230000014509 gene expression Effects 0.000 description 1
• 239000012362 glacial acetic acid Substances 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 125000005843 halogen group Chemical group 0.000 description 1
• 230000009931 harmful effect Effects 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 239000008241 heterogeneous mixture Substances 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• 150000004678 hydrides Chemical class 0.000 description 1
• 150000003840 hydrochlorides Chemical class 0.000 description 1
• 150000002431 hydrogen Chemical class 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 206010020718 hyperplasia Diseases 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
• APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 230000003914 insulin secretion Effects 0.000 description 1
• UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 150000004694 iodide salts Chemical class 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 230000003907 kidney function Effects 0.000 description 1
• 201000008627 kidney hypertrophy Diseases 0.000 description 1
• 238000011813 knockout mouse model Methods 0.000 description 1
• 150000003893 lactate salts Chemical class 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• DBTNVRCCIDISMV-UHFFFAOYSA-L lithium;magnesium;propane;dichloride Chemical compound [Li+].[Mg+2].[Cl-].[Cl-].C[CH-]C DBTNVRCCIDISMV-UHFFFAOYSA-L 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 1
• 229910001623 magnesium bromide Inorganic materials 0.000 description 1
• 239000000395 magnesium oxide Substances 0.000 description 1
• CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
• VFZXMEQGIIWBFJ-UHFFFAOYSA-M magnesium;cyclopropane;bromide Chemical compound [Mg+2].[Br-].C1C[CH-]1 VFZXMEQGIIWBFJ-UHFFFAOYSA-M 0.000 description 1
• AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
• 150000002688 maleic acid derivatives Chemical class 0.000 description 1
• 150000004701 malic acid derivatives Chemical class 0.000 description 1
• 150000002739 metals Chemical class 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
• HVXCOVWKISGSMO-UHFFFAOYSA-N methyl 2-(5-ethoxypyridin-3-yl)-2,3-dihydro-1,4-benzodioxine-5-carboxylate Chemical compound COC(=O)C1=CC=CC=2OC(COC=21)C=1C=NC=C(C=1)OCC HVXCOVWKISGSMO-UHFFFAOYSA-N 0.000 description 1
• GFRWSPMOAVBWMW-UHFFFAOYSA-N methyl 2-[5-(4-hydroxyoxan-4-yl)pyridin-3-yl]-2,3-dihydro-1,4-benzodioxine-5-carboxylate Chemical compound COC(=O)C1=CC=CC=2OC(COC=21)C=1C=NC=C(C=1)C1(CCOCC1)O GFRWSPMOAVBWMW-UHFFFAOYSA-N 0.000 description 1
• OSTGWHVYMZDROH-UHFFFAOYSA-N methyl 2-[5-(hydroxymethyl)pyridin-3-yl]-2,3-dihydro-1,4-benzodioxine-5-carboxylate Chemical compound COC(=O)C1=CC=CC=2OC(COC=21)C=1C=NC=C(C=1)CO OSTGWHVYMZDROH-UHFFFAOYSA-N 0.000 description 1
• NUQJTNUHWDXUDS-UHFFFAOYSA-N methyl 2-[5-(methylsulfinylmethyl)pyridin-3-yl]-2,3-dihydro-1,4-benzodioxine-5-carboxylate Chemical compound COC(=O)C1=CC=CC=2OC(COC=21)C=1C=NC=C(C=1)CS(=O)C NUQJTNUHWDXUDS-UHFFFAOYSA-N 0.000 description 1
• FJKKKNSKPGEVGM-UHFFFAOYSA-N methyl 2-[5-[1-(2-methylpropanoyl)piperidin-4-yl]oxypyridin-3-yl]-2,3-dihydro-1,4-benzodioxine-5-carboxylate Chemical compound COC(=O)C1=CC=CC=2OC(COC=21)C=1C=NC=C(C=1)OC1CCN(CC1)C(C(C)C)=O FJKKKNSKPGEVGM-UHFFFAOYSA-N 0.000 description 1
• AAJZXPWBILCHAW-UHFFFAOYSA-N methyl 5-bromopyridine-3-carboxylate Chemical compound COC(=O)C1=CN=CC(Br)=C1 AAJZXPWBILCHAW-UHFFFAOYSA-N 0.000 description 1
• LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical class CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
• 150000005451 methyl sulfates Chemical class 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 239000002395 mineralocorticoid Substances 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 230000002107 myocardial effect Effects 0.000 description 1
• YCJZWBZJSYLMPB-UHFFFAOYSA-N n-(2-chloropyrimidin-4-yl)-2,5-dimethyl-1-phenylimidazole-4-carboxamide Chemical compound CC=1N(C=2C=CC=CC=2)C(C)=NC=1C(=O)NC1=CC=NC(Cl)=N1 YCJZWBZJSYLMPB-UHFFFAOYSA-N 0.000 description 1
• QYZFTMMPKCOTAN-UHFFFAOYSA-N n-[2-(2-hydroxyethylamino)ethyl]-2-[[1-[2-(2-hydroxyethylamino)ethylamino]-2-methyl-1-oxopropan-2-yl]diazenyl]-2-methylpropanamide Chemical compound OCCNCCNC(=O)C(C)(C)N=NC(C)(C)C(=O)NCCNCCO QYZFTMMPKCOTAN-UHFFFAOYSA-N 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• MERIVZAHHVOBCI-UHFFFAOYSA-N naphthalene-1-carboperoxoic acid Chemical class C1=CC=C2C(C(=O)OO)=CC=CC2=C1 MERIVZAHHVOBCI-UHFFFAOYSA-N 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 210000000885 nephron Anatomy 0.000 description 1
• 150000002823 nitrates Chemical class 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 230000036542 oxidative stress Effects 0.000 description 1
• 235000019161 pantothenic acid Nutrition 0.000 description 1
• 230000003076 paracrine Effects 0.000 description 1
• 230000008289 pathophysiological mechanism Effects 0.000 description 1
• 230000036513 peripheral conductance Effects 0.000 description 1
• 150000002978 peroxides Chemical class 0.000 description 1
• 230000003285 pharmacodynamic effect Effects 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
• WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
• 235000021317 phosphate Nutrition 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 1
• 231100000683 possible toxicity Toxicity 0.000 description 1
• BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 1
• 229910000160 potassium phosphate Inorganic materials 0.000 description 1
• 235000011009 potassium phosphates Nutrition 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 238000002953 preparative HPLC Methods 0.000 description 1
• 238000012746 preparative thin layer chromatography Methods 0.000 description 1
• 239000000186 progesterone Substances 0.000 description 1
• 229960003387 progesterone Drugs 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• OGHBATFHNDZKSO-UHFFFAOYSA-N propan-2-olate Chemical compound CC(C)[O-] OGHBATFHNDZKSO-UHFFFAOYSA-N 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 230000009103 reabsorption Effects 0.000 description 1
• 230000035484 reaction time Effects 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 238000006722 reduction reaction Methods 0.000 description 1
• 238000010992 reflux Methods 0.000 description 1
• 201000002793 renal fibrosis Diseases 0.000 description 1
• 238000012959 renal replacement therapy Methods 0.000 description 1
• 230000002336 repolarization Effects 0.000 description 1
• SVOOVMQUISJERI-UHFFFAOYSA-K rhodium(3+);triacetate Chemical compound [Rh+3].CC([O-])=O.CC([O-])=O.CC([O-])=O SVOOVMQUISJERI-UHFFFAOYSA-K 0.000 description 1
• 150000003873 salicylate salts Chemical class 0.000 description 1
• 239000012047 saturated solution Substances 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 238000009097 single-agent therapy Methods 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 1
• LYPGDCWPTHTUDO-UHFFFAOYSA-M sodium;methanesulfinate Chemical compound [Na+].CS([O-])=O LYPGDCWPTHTUDO-UHFFFAOYSA-M 0.000 description 1
• 239000003270 steroid hormone Substances 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 238000001308 synthesis method Methods 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 150000003892 tartrate salts Chemical class 0.000 description 1
• 229910052714 tellurium Inorganic materials 0.000 description 1
• PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 description 1
• IVUYDHHSJSZVLM-UHFFFAOYSA-N tert-butyl N-[[5-(5-carbamoyl-2,3-dihydro-1,4-benzodioxin-2-yl)pyridin-3-yl]methyl]carbamate Chemical compound C(C)(C)(C)OC(NCC=1C=NC=C(C=1)C1COC2=C(O1)C=CC=C2C(N)=O)=O IVUYDHHSJSZVLM-UHFFFAOYSA-N 0.000 description 1
• LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
• VZPOHASZICQBDX-UHFFFAOYSA-N tert-butyl n-[(5-bromopyridin-3-yl)methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CN=CC(Br)=C1 VZPOHASZICQBDX-UHFFFAOYSA-N 0.000 description 1
• FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
• 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
• 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
• 125000000464 thioxo group Chemical group S=* 0.000 description 1
• 210000001519 tissue Anatomy 0.000 description 1
• 239000010936 titanium Substances 0.000 description 1
• 229910052719 titanium Inorganic materials 0.000 description 1
• LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical group C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 1
• NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 1
• 210000005239 tubule Anatomy 0.000 description 1
• 230000004218 vascular function Effects 0.000 description 1
• 210000005166 vasculature Anatomy 0.000 description 1
• 206010047302 ventricular tachycardia Diseases 0.000 description 1
• 235000008979 vitamin B4 Nutrition 0.000 description 1
• 239000003643 water by type Substances 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 235000021119 whey protein Nutrition 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1
• XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1